Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)

Active:	No
Cancer Type:	Hematopoietic Malignancies Leukemia Unknown Primary	NCT ID:	NCT01348490
Trial Phases:	Phase II	Protocol IDs:	INCB18424-258 (primary)
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Incyte Corporation
NCI Full Details:	http://clinicaltrials.gov/show/NCT01348490

Summary

To evaluate the effects of treatment with ruxolitinib (INCB018424) on spleen volume,
symptoms and potential side effects in participants with PMF, PPV-MF and PET-MF who have
platelet counts of 50 x 10^9/L to 100 x 10^9/L. It is anticipated that individualized
dose optimization from the starting ruxolitinib level of 5 mg bid will be associated with
reductions in splenomegaly, MF-associated symptoms and inflammatory cytokine levels.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

Study Coordinator:

Wilena Session
404-778-5319

Doctors:

Martha L. Arellano MD

Elliott F. Winton MD

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.